Look before you leap: Genomic screening in obstetrics and gynecology

Obstetrics and Gynecology

Volumn 125, Issue 6, 2015, Pages 1299-1305

  Adams, Michael C ^a   Berg, Jonathan S ^a   Pearlman, Mark D ^a   Vora, Neeta L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADVERSE OUTCOME; CANCER RISK; CHROMOSOME ABERRATION; COST EFFECTIVENESS ANALYSIS; DOWN SYNDROME; FAMILY HISTORY; GENE MUTATION; GENERAL PRACTICE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; GENETICS; GENOMICS; GYNECOLOGIST; GYNECOLOGY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; LOW RISK PATIENT; MEDICAL EDUCATION; NON INVASIVE PROCEDURE; OBSTETRICIAN; OBSTETRICS; POPULATION GENETICS; PREDICTIVE VALUE; PREGNANCY TERMINATION; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RESIDENCY EDUCATION; REVIEW; COST BENEFIT ANALYSIS; EDUCATION; FEMALE; LABORATORY DIAGNOSIS; MASS SCREENING; MUTATION; PREGNANCY; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; COST-BENEFIT ANALYSIS; FALSE POSITIVE REACTIONS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC TESTING; GENETICS; GENOMICS; GYNECOLOGY; HUMANS; MASS SCREENING; MUTATION; OBSTETRICS; PREDICTIVE VALUE OF TESTS; PREGNANCY;

EID: 84929903122     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000871     Document Type: Review

References (19)

1. King M, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 2014;312: 1091-2.
2. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014;370:799-808.
3. Norton ME, Jelliffe-Pawlowski LL, Currier RJ. Chromosome abnormalities detected by current prenatal screening and non-invasive prenatal testing. Obstet Gynecol 2014;124:979-86.
4. Bellcross CA, Kolor K, Goddard KAB, Coates RJ, Reyes M, Khoury MJ. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 2011; 40:61-6.
5. Cleary-Goldman J, Morgan MA, Malone FD, Robinson JN, D'Alton ME, Schulkin J. Screening for Down syndrome: practice patterns and knowledge of obstetricians and gynecologists. Obstet Gynecol 2006;107:11-7.
6. Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, et al. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Cancer Netw 2014; 12:1326-38.
7. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci 2014;111:14205-10.
8. Ayres AC, Whitty JA, Ellwood DA. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program. Aust N Z J Obstet Gynaecol 2014;54:412-7.
9. Dar P, Curnow KJ, Gross SJ, Hall MP, Stosic M, Demko Z, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneu-ploidy testing. Am J Obstet Gynecol 2014;211:527.e1-17.
10. Wilson JMG, Jungner G; World Health Organization. Principles and practice of screening for disease. 1968. Available at: http://apps.who.int//iris/handle/10665/37650. Retrieved February 21, 2015.
11. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008;10:294-300.
12. Pruss D, Morris B, Hughes E, Eggington JM, Esterling L, Robinson BS, et al. Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 2014;147: 119-32.
13. Tavtigian SV, Greenblatt MS, Goldgar DE, Boffetta P; IARC Unclassified Genetic Variants Working Group. Assessing patho-genicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Hum Mutat 2008;29:1261-4.
14. Rahman N. Realizing the promise of cancer predisposition genes. Nature 2014;505:302-8.
15. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013;9:e1003212.
16. Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med 2011;13:998-1005.
17. Lindor NM, Goldgar DE, Tavtigian SV, Plon SE, Couch FJ. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. Oncologist 2013;18:518-24.
18. Kuppermann M, Pena S, Bishop JT, Nakagawa S, Gregorich SE, Sit A, et al. Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: a randomized clinical trial. JAMA 2014;312:1210-7.
19. Grati FR, Barlocco A, Grimi B, Milani S, Frascoli G, Di Meco AM, et al. Chromosome abnormalities investigated by non-invasive prenatal testing account for approximately 50% of fetal unbalances associated with relevant clinical phenotypes. Am J Med Genet A 2010;152A:1434-42.